DE69612874D1 - Arylethensulfonamid-derivate und diese enthaltende medikamente - Google Patents

Arylethensulfonamid-derivate und diese enthaltende medikamente

Info

Publication number
DE69612874D1
DE69612874D1 DE69612874T DE69612874T DE69612874D1 DE 69612874 D1 DE69612874 D1 DE 69612874D1 DE 69612874 T DE69612874 T DE 69612874T DE 69612874 T DE69612874 T DE 69612874T DE 69612874 D1 DE69612874 D1 DE 69612874D1
Authority
DE
Germany
Prior art keywords
optionally substituted
halogens
carboxy
drugs
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69612874T
Other languages
English (en)
Other versions
DE69612874T2 (de
Inventor
Hironori Harada
Jun-Ichi Kazami
Susumu Watanuki
Ryuji Tsuzuki
Katsumi Sudou
Akihiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of DE69612874D1 publication Critical patent/DE69612874D1/de
Application granted granted Critical
Publication of DE69612874T2 publication Critical patent/DE69612874T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE69612874T 1995-12-20 1996-12-19 Arylethensulfonamid-derivate und diese enthaltende medikamente Expired - Lifetime DE69612874T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33211195 1995-12-20
PCT/JP1996/003701 WO1997022595A1 (fr) 1995-12-20 1996-12-19 Derives arylethenesulfonamide et composition de medicaments renfermant ces derives

Publications (2)

Publication Number Publication Date
DE69612874D1 true DE69612874D1 (de) 2001-06-21
DE69612874T2 DE69612874T2 (de) 2001-10-04

Family

ID=18251283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69612874T Expired - Lifetime DE69612874T2 (de) 1995-12-20 1996-12-19 Arylethensulfonamid-derivate und diese enthaltende medikamente

Country Status (14)

Country Link
US (1) US6083955A (de)
EP (1) EP0882719B1 (de)
JP (1) JP3087968B2 (de)
KR (1) KR100456650B1 (de)
CN (1) CN1102580C (de)
AT (1) ATE201202T1 (de)
AU (1) AU703386B2 (de)
BR (1) BR9612061A (de)
DE (1) DE69612874T2 (de)
ES (1) ES2156305T3 (de)
HU (1) HUP0000474A3 (de)
RU (1) RU2172735C2 (de)
TW (1) TW414792B (de)
WO (1) WO1997022595A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
EE04156B1 (et) 1997-04-28 2003-10-15 Texas Biotechnology Corporation Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
HUP0204168A2 (hu) * 1999-12-22 2003-04-28 Actelion Pharmaceuticals Ltd. Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
AU2464301A (en) 1999-12-31 2001-07-16 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0003234D0 (en) * 2000-02-11 2000-04-05 Pfizer Ltd Method of treatment
DE60032517T2 (de) * 2000-02-16 2007-10-04 Astellas Pharma Inc. Heilmittel gegen durch endothelin verursachte erkrankungen
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
GB0023074D0 (en) * 2000-09-20 2000-11-01 Pfizer Ltd Pyridazines
ES2333409T3 (es) 2000-09-25 2010-02-22 Actelion Pharmaceuticals Ltd. Arilalcano-sulfonamidas dotadas de actividad antagonistas de la endotelina.
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1345920B1 (de) 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Neue sulfamiden und deren verwendung als endothelin-antagonisten
CA2434833A1 (en) * 2001-02-09 2002-08-22 Hironori Harada Pharmaceutical composition for treating chronic heart failure
WO2002080924A1 (fr) * 2001-04-03 2002-10-17 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle utilisation du derive sulfonamide arylethene
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
EP1393731A1 (de) * 2001-04-13 2004-03-03 Yamanouchi Pharmaceutical Co. Ltd. Neuartige verwendung eines arylethensulfonamid-derivats
JPWO2003010152A1 (ja) * 2001-07-27 2004-11-18 山之内製薬株式会社 アリールエテンスルホンアミド誘導体の新規結晶及びその製造法
DE60224223T2 (de) * 2002-01-02 2008-12-04 Actelion Pharmaceuticals Ltd. Neue alkylsulfonamide als endothelinantagonisten
ES2320649T3 (es) 2002-12-02 2009-05-27 Actelion Pharmaceuticals Ltd. Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina.
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1729749A2 (de) 2004-03-17 2006-12-13 Novartis AG Verwendung von renininhibitoren in therapie
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US20080233188A1 (en) 2005-09-12 2008-09-25 Actelion Pharmaceuticals Ltd. Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
CN112778215B (zh) * 2021-01-29 2023-06-20 中国医科大学 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
CN112898208B (zh) * 2021-01-29 2023-06-20 中国医科大学 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5222003A (en) * 1975-08-13 1977-02-19 Hitachi Ltd Process for removing hydrogen sulfide from hot gas
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (de) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (de) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
JPH07332111A (ja) * 1994-06-07 1995-12-22 Nippon Muki Co Ltd 吸気フィルタ装置

Also Published As

Publication number Publication date
JP3087968B2 (ja) 2000-09-18
AU1171097A (en) 1997-07-14
CN1102580C (zh) 2003-03-05
HUP0000474A3 (en) 2001-06-28
ES2156305T3 (es) 2001-06-16
RU2172735C2 (ru) 2001-08-27
KR20000064423A (ko) 2000-11-06
EP0882719B1 (de) 2001-05-16
WO1997022595A1 (fr) 1997-06-26
KR100456650B1 (ko) 2005-06-20
AU703386B2 (en) 1999-03-25
HUP0000474A2 (hu) 2000-12-28
US6083955A (en) 2000-07-04
BR9612061A (pt) 1999-02-23
EP0882719A1 (de) 1998-12-09
DE69612874T2 (de) 2001-10-04
EP0882719A4 (de) 1999-04-28
CN1204326A (zh) 1999-01-06
TW414792B (en) 2000-12-11
ATE201202T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
DE69612874D1 (de) Arylethensulfonamid-derivate und diese enthaltende medikamente
DE69428977D1 (de) Arzneimittel gegen Parkinsonsche Krankheit
ATE142630T1 (de) Triazin-derivate und unkrautvertilgungsmittel daraus
IL119729A0 (en) Heterocyclic compounds having tachykinin receptor antagonist activity pharmaceutical compositions containing the same and processes for the preparation thereof
FI950016A0 (fi) Heterosykliset yhdisteet lääkeaineena
EP1700856A4 (de) Thiazolderivat
DE69728761D1 (de) Heterocyclisch substituierte benzolderivate und herbizide
ATE154354T1 (de) Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
ATE207922T1 (de) Carbapenem-derivate
CA2297486A1 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
KR930019669A (ko) 신놀린-3-카르복실산 유도체
ATE137501T1 (de) Benzazin-verbindungen und deren pharmazeutische verwendungen
ATE402151T1 (de) 2-(arylphenyl)amino-imidazolin-derivate
ATE361284T1 (de) 1-cyclamino-alkylcyclohexan-derivate, diese enthaltende pharmazeutische zusammensetzungen, und ihre verwendung als anticonvulsia
DE69426620D1 (de) Antidepressiva
ATE170851T1 (de) Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten
DK0552712T3 (da) 8-(1-aminocycloalkyl)1,3-dialkylxanthinderivater som antagonister for adenosinreceptorer
NZ513203A (en) Pyrrolo [2,1-c][1,2,4] benzothiadiazine compounds and pharmaceutical use as AMPA modulators
FR2793248B1 (fr) Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0982029A4 (de) Vorbeugende /heilmittel fuer arteriosklerose
DE69815158D1 (de) Heteroaromatische verbindungen
TH32747A (th) อนุพันธ์พิริมิดีนชนิดใหม่

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP